Independent information resource
Guides, comparison frameworks, research summaries, and plain-language context for people evaluating how ibogaine programmes differ.
Information is not a substitute for medical assessment or emergency planning.
What this page offers
Quiet Harbor 55 provides information services for people who want to examine ibogaine programme claims carefully, compare stated safeguards, and keep uncertainty visible rather than overlooked.
Our core ibogaine programme overview starts with the practical questions that can shape a decision: what a programme says it is for, what it discloses about screening and monitoring, and where its account leaves important questions unanswered. The work is informational only; it is not a recommendation, referral, or clinical service.
“Safety before claims means treating missing information as information, too.”
Information offerings
These resources are designed to make programme differences easier to see without presenting ibogaine as proven, routine, or low risk.
Plain-language guides separate broad treatment-use claims from the practical details people may need to examine: stated goals, setting, screening, monitoring, and follow-up. The principles behind this independent resource explain why cautious language and clear limits matter.
Comparison frameworks organise visible differences in programme models without scoring providers or predicting outcomes. They focus on what is disclosed, what needs verification, and which questions may warrant professional input.
Research summaries distinguish preliminary findings from established evidence and note what study design can and cannot show. NIDA’s overview of psychedelics research similarly describes an active research area rather than a settled treatment standard.
A practical glossary and question sets help families and individuals clarify unfamiliar terminology, compare stated safeguards, and describe concerns precisely. For wider context on ibogaine itself, ibogaine and 5-MeO-DMT context can be considered alongside claims made by individual programmes.
A usable lens
A useful comparison holds several dimensions together instead of allowing a single reassuring claim to stand in for the whole picture.
Evidence and risk
Ibogaine has been associated with significant safety concerns, including effects on cardiac rhythm. The FDA’s description of drug development and approval is useful context for why experimental or investigational interest is not the same thing as established safety and effectiveness.
The aim here is not to make a treatment decision on anyone’s behalf. It is to help people identify the claims being made, the safeguards being described, and the points where an appropriately qualified medical professional must assess individual circumstances.
Common questions
These answers describe the boundaries of the resource and the purpose of its comparison tools.
No. Quiet Harbor 55 is an independent information resource. It does not provide diagnosis, screening, treatment, referrals, or medical advice.
A comparison framework can help identify differences in stated screening, medical oversight, emergency planning, setting, follow-up, and how evidence or uncertainty is described. It cannot verify a programme’s claims or determine whether a programme is appropriate for an individual.
Ibogaine is associated with serious risks, including cardiac risks. Information should never substitute for individualized assessment by appropriately qualified medical professionals; the general ibogaine overview also notes its complex pharmacology and safety concerns.
Keep the question open
Use the programme materials as a starting point for scrutiny—not as proof that an intervention is safe, suitable, or likely to produce a particular outcome.